Cholamandalam Financial Holdings Ltd (CHOLAHLDNG) Q2 FY27 Results Analysis: Disbursements Surge 47%, Insurance Slips to Loss
Cholamandalam Financial Holdings Ltd's Q2 FY27 numbers came in strong, with revenue of Rs. 11,388.41 Cr (+18.90% YoY) and PAT growth of +25.19% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | November 06, 2026 |
|---|---|
| Revenue (Q2) | Rs. 11,388.41 Cr (+18.90% YoY) |
| PAT (Q2) | Rs. 1,520.11 Cr (+25.19% YoY) |
| EPS (Q2) | Rs. 34.22 (+16.87% YoY) |
Quarter Snapshot
Lending momentum is the story: CIFCL disbursements grew 47% YoY and AUM 23% YoY, at the top of the 20-23% guidance band, driving financing segment profit up 39.78% YoY with 270 bps margin expansion. The offset is the insurance segment flipping to a Rs.169.09 Cr pre-tax loss on NATCAT and Motor OD claims, plus a 22.78% QoQ employee-cost jump, which cut consolidated PAT 15.02% QoQ despite 25.19% YoY growth. H2 profitability targets (ROTA ≥4.2%, Chola MS ROE recovery) remain the binding questions rather than growth.
Q2 FY27 Expectations vs Results
| Driver | Expected before results | What happened | Verdict |
|---|---|---|---|
| Growth vs guide | "ahead to in-line" — accelerating system credit and record vehicle retails support the 22–23% AUM guide | AUM +23% YoY (Rs.2,68,009 Cr); disbursements +47% | Played out |
| Q2 margin bridge | "NIM likely flat to modestly compressing… risk is forward" | interest income +5.61% QoQ vs finance costs +8.16% QoQ; financing margin 23.59% vs 25.09% Q1 (NIM itself not disclosed in filing) — modest in-quarter compression, forward risk intact | Partially |
| Chola MS cost headwind | EOM paper + Shishu Pal ruling + motor OD tide "moving the other way" | insurance segment PBT loss Rs.169.09 Cr; CMSGICL post-tax loss Rs.120 Cr on NATCAT + motor OD | Played out |
| Cost-of-funds guide (~10 bps H2) | "direction of risk is to the high side" | finance costs +23.22% YoY, +8.16% QoQ — direction | Played out |
| Watch: motor OD loss-ratio glide path (Q2 = first checkpoint) | improvement expected over "couple of quarters" | filing cites elevated motor OD claims; ratio not disclosed | Not observable from the filing |
| Watch: incremental motor TP provisions / review petition | peers took Q1 provisions; petition pending | nothing disclosed in the Q2 filing — remains open for the call | Not addressed in the filing |
| Watch: EOM consultation read-through; IFRS preliminary observations (effective Apr 1, 2027) | management assessment expected on the call | filing notes cover only labour codes and the Ind AS forbearance till Mar 31, 2027 — remains open for the call | Not addressed in the filing |
Read our full results preview.
Management Guidance vs Delivery
| What management said | Where | What happened | Verdict |
|---|---|---|---|
| CIFCL AUM growth 20%–23% (FY27) | Q4 FY26/Q1 FY27 earnings calls ("still holding to the 22-23% growth guidance") | AUM Rs.2,68,009 Cr, +23% YoY | On Track |
| CIFCL disbursement growth 12%–15% (FY27) | Q4 FY26 earnings call | Q2 disbursements Rs.35,872 Cr, +47% YoY | On Track |
| CIFCL net NPA 1.5% by FY27-end | CIFCL management commentary, Q1 FY27 | achieved in Q1 FY27, ahead of goal (per prior-quarter disclosures); not re-disclosed this quarter | Met |
| Chola MS motor OD loss ratio to high-70s "within a couple of quarters" | Q1 FY27 earnings call | press release cites "elevated claim experience in Motor OD segment"; ratio not disclosed — first checkpoint went the wrong way | Too Early |
| Chola MS ROE 16%–18% IGAAP medium-term; "15% plus" medium-to-long term | Q2 FY26/Q4 FY26 earnings calls | Q2 post-tax loss Rs.120 Cr; H1 PAT Rs.8 Cr vs Rs.165 Cr — trajectory currently adverse | Too Early |
| Growth momentum intact across major businesses | Q1 FY27 call (chairman's statement quoted in prior-quarter notes) | Q2 disbursements +47%, AUM +23% (press release) | Confirmed |
| No additional credit overlays required | Q4 FY26 call | impairment on financial instruments fell 3.58% YoY / 6.18% QoQ | Confirmed |
| Insurance ROE recovery toward 16%–18% | Q2 FY26/Q4 FY26 calls | insurance segment swung to a Rs.169.09 Cr PBT loss | Contradicted for now |
| Vehicle down-cycle turning | Q4 FY26/Q1 FY27 calls | not testable from the consolidated filing — no vehicle-finance split disclosed | Too Early |
Key Numbers, Quarter by Quarter
| Metric | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|---|
| CIFCL disbursement growth | +16% | +25% | +22% | +47% |
| CIFCL AUM growth | +21% | +21% | +23% | +23% |
| Chola MS GWP growth | n.d. | n.d. | +6% | +7% |
Key Investment Insights
Key Positives
- CIFCL disbursements grew 47% YoY to Rs.35,872 Cr in Q2, well ahead of the 12-15% FY27 guidance
- CIFCL AUM grew 23% YoY to Rs.2,68,009 Cr, at the top of the 20-23% FY27 guidance band
- Financing segment result grew 39.78% YoY to Rs.2,187.05 Cr with margin up 270 bps YoY to 23.59%
- Consolidated PAT grew 25.19% YoY to Rs.1,520.11 Cr; H1 PAT grew 33.76% YoY
- Fee & commission income grew 45.19% YoY to Rs.767.04 Cr
- Impairment on financial instruments fell 3.58% YoY to Rs.865.27 Cr
- Loan growth of 10.39% since March was funded with borrowings up 9.91%, including Rs.4,000 Cr of new subordinated liabilities
Risk Factors
- Insurance segment flipped to a pre-tax loss of Rs.169.09 Cr (vs +Rs.61.94 Cr YoY) with Chola MS posting a Q2 post-tax loss of Rs.120.03 Cr on NATCAT events and elevated Motor OD claims
- Net insurance claims grew 16.74% YoY against 9.54% gross premium growth and only 1.64% insurance segment revenue growth
- Employee benefits expense rose 30.67% YoY and 22.78% QoQ, with the QoQ rise unexplained in the filing
- PAT fell 15.02% QoQ and owners' PAT fell 20.27% QoQ
- Finance costs grew 8.16% QoQ vs interest income +5.61%, an early spread-squeeze signature
- NCI absorbed 57.73% of consolidated PAT (54.70% in Q2 FY26) due to the 60%-owned insurer's loss
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.